Medical Condition News

RSS

Eating Mediterranean-style diet reduces heart disease risk: Research

A study of twins shows that even with genes that put them at higher risk of cardiovascular disease, eating a Mediterranean-style diet can improve heart function, according to research reported in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

16 Jun 2010

Florida Advisory Council on Radiation Protection endorses ASTRO's Target Safely patient protection plan

Through a unanimous decision, the Florida Advisory Council on Radiation Protection has endorsed Target Safely, the American Society for Radiation Oncology's (ASTRO) patient protection plan.

16 Jun 2010

Course on cancer rehabilitation for nurses and other health professionals

Nurses and other health professionals will soon be able to take a dedicated course on cancer rehabilitation at Swansea University. The master's module in cancer rehabilitation is being launched to help the training of health and social care staff.

16 Jun 2010

NIH awards Geisinger $1.8M grant for study of nuclear ErbB3 protein

A new five-year, $1.8 million National Institutes of Health grant awarded to staff scientist Nikolaos Tapinos, M.D., Ph.D., of Geisinger's Sigfried and Janet Weis Center for Research will be used to study the role of nuclear ErbB3 protein during development of the nervous system and in response to nerve injury.

16 Jun 2010

Cancer overtreatment raises concern; Physicians tend to use new technology even before solid evidence backs it

The Associated Press/Arizona Republic: "It's an unthinkable notion for a generation raised on the message that early cancer detection saves lives, but specialists say more tumors actually are being found too early. That is raising uncomfortable questions about how aggressively to treat early growths -- in some cases, even how aggressively to test -- along with a push for more of the informed-choice programs.

16 Jun 2010

New cancer research centre launched in Edinburgh

Edinburgh today (Wednesday) becomes the next link in a unique chain of Cancer Research UK Centres that are being launched across the UK.

16 Jun 2010

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

QLT Inc. today announced that final results from the Novartis-sponsored Phase IIIb DENALI study were presented on June 8, 2010 during the World Ophthalmology Congress in Berlin. DENALI was a 24-month randomized, double-masked, multicenter trial in patients with subfoveal choroidal neovascularization secondary to wet age-related macular degeneration (all lesion types).

16 Jun 2010

New combination appears to be effective against cancer stem cells in pancreatic cancer

The new cancer medication sorafenib looks promising. Sorafenib is used for advanced liver and kidney cancer and also appears to be effective against cancer stem cells in pancreatic cancer. The team led by Professor Dr. Ingrid Herr, Head of the Department of Molecular Oncosurgery, a group of the Department of Surgery at Heidelberg University Hospital, (Managing Director: Professor Dr. Markus W. B-chler) in cooperation with the German Cancer Research Center, tested the new substance in mice and pancreatic cancer cells.

16 Jun 2010

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the dosing of the first patient in a Phase I/II clinical trial of the doxorubicin conjugate of milatuzumab for the treatment of patients with relapsed multiple myeloma.

16 Jun 2010

ARBs may be linked with increased risk of developing cancer: US scientists

A common class of blood pressure drugs called angiotensin-receptor blockers may be linked with a slightly increased risk of developing cancer, US scientists have found.

16 Jun 2010

LMBRI, Lipopharma Therapeutics collaborate to promote cancer drug development, improve patient outcomes

LMBRI LLC and Lipopharma Therapeutics SL today announced collaboration aimed at transforming cancer drug development and improving patient outcomes. Lipopharma developed new assessment approaches, methods and technologies for developing cancer therapeutics and diagnostics using their proprietary design of structure-based molecules that regulate the structure and functions of the membrane lipids, instead targeting cellular proteins, called "Membrane Lipid-Therapy".

16 Jun 2010

UOHI tests Canada's first in-hospital program to screen and treat patients for diabetes

The University of Ottawa Heart Institute is testing Canada's first in-hospital program to screen and treat patients for diabetes, a growing epidemic in much of the Western world. The program is expected to lead to new ways to identify and cope with one of the most important risk factors for heart disease, particularly in women.

16 Jun 2010

BIOCIUS Life Sciences, BlueSky Biotech collaborate to offer Sirtuin pre-validated assay solution

BIOCIUS Life Sciences Inc., developers of the RapidFire® high-throughput mass spectrometry system, and BlueSky Biotech, service provider of discovery biologicals, today announced their collaboration to offer the industry's only Sirtuin (SIRT, silent mating type information regulation homolog) enzyme preparations fully-validated in a label-free functional assay.

16 Jun 2010

Researchers examine rates of cancer in British white and British Indian population

British Indians have fewer cases of many different cancers including breast, prostate, colon and lung than the British white population, according to new research published in the British Journal of Cancer1 today (Wednesday).

16 Jun 2010

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Biogen Idec today announced enrollment of the first patient in a multicenter Phase II clinical trial designed to evaluate its investigational oral therapy BG-12 (dimethyl fumarate) in combination with commonly used first-line treatments in patients with relapsing-remitting multiple sclerosis (RRMS).

15 Jun 2010

Epocal receives FDA marketing clearance for new lactate test on epoc Blood Analysis System

Epocal, Inc., a leading edge provider of point of care technology, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market its new lactate test on the epoc Blood Analysis System. Lactate measurements from the epoc System are used to evaluate acid-base status and for diagnosis and treatment of lactic acidosis (abnormally high acidity of the blood).

15 Jun 2010

Positive clinical trial results for Anacor Pharmaceuticals' AN2728 announced

Anacor Pharmaceuticals today announced positive clinical trial results for its lead phosphodiesterase-4 inhibitor, AN2728, a novel topical anti-inflammatory compound derived from Anacor's boron chemistry platform. These results were obtained from a multi-center, Phase 2b, randomized, double-blind, dose-ranging, bilateral trial comparing AN2728 ointment, 0.5% and 2.0%, applied once or twice daily, to vehicle in 145 patients with mild-to-moderate plaque-type psoriasis.

15 Jun 2010

Endosense launches ProForce Registry Study of TactiCath force-sensing ablation catheter

Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment of the first patients in its ProForce Registry. The news marks the launch of the ProForce Registry Study, an international, single arm, multi-center, post-market trial of Endosense's TactiCath force-sensing ablation catheter.

15 Jun 2010

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.

15 Jun 2010

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Orasi Medical today announced that it has entered an agreement with H. Lundbeck A/S to study the effect of Lundbeck central nervous system compounds on the human brain.

15 Jun 2010

Medical Condition News

Eating Mediterranean-style diet reduces heart disease risk: Research

Florida Advisory Council on Radiation Protection endorses ASTRO's Target Safely patient protection plan

Course on cancer rehabilitation for nurses and other health professionals

NIH awards Geisinger $1.8M grant for study of nuclear ErbB3 protein

Cancer overtreatment raises concern; Physicians tend to use new technology even before solid evidence backs it

New cancer research centre launched in Edinburgh

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

New combination appears to be effective against cancer stem cells in pancreatic cancer

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

ARBs may be linked with increased risk of developing cancer: US scientists

LMBRI, Lipopharma Therapeutics collaborate to promote cancer drug development, improve patient outcomes

UOHI tests Canada's first in-hospital program to screen and treat patients for diabetes

BIOCIUS Life Sciences, BlueSky Biotech collaborate to offer Sirtuin pre-validated assay solution

Researchers examine rates of cancer in British white and British Indian population

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Epocal receives FDA marketing clearance for new lactate test on epoc Blood Analysis System

Positive clinical trial results for Anacor Pharmaceuticals' AN2728 announced

Endosense launches ProForce Registry Study of TactiCath force-sensing ablation catheter

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Membrane proteins in focus: Turning high-risk targets into routine workflows

How metabolic phenotyping can detect viral infections in minutes

Directed enzyme evolution and the Nobel Prize: Making enzymes evolve in the lab

Latest News